CCRC Recapitalized by Martis Capital Via Its Newly Formed Clinical Research Site Platform, Alcanza Clinical Research

March 16, 2022


Coastal Carolina Research Center has been recapitalized by Martis Capital via its newly formed clinical research site platform, Alcanza Clinical Research.


The highly fragmented and rapidly-consolidating clinical research site industry represents a ~$21B global market; nearly 400,000 studies are conducted annually. After the global pandemic further highlighted the importance of clinical research and trials, the market demands more efficient and diverse patient recruitment across a broad range of therapeutic areas and patient populations.

Coastal Carolina Research Center (CCRC) performs clinical research trials at its dedicated medical research facility in North Charleston, SC. The company provides access for thousands of Charleston Lowcountry citizens who are interested in volunteering for and participating in clinical trials and research studies that focus primarily on “outpatient” studies in multiple therapeutic areas and diseases. CCRC’s access to diverse patient populations made them the ideal target for Martis Capital’s newly formed clinical research platform, Alcanza Clinical Research.

Crosstree’s Role

Crosstree acted as exclusive financial advisor to CCRC as in its recapitalization by Martis Capital through:

  • Positioning CCRC to maximize value
  • Evaluating multiple buyers and bids to determine the optimal outcome for CCRC shareholders
  • Leveraging market expertise to identify the ideal transaction partner to drive future growth